Options in thrombosis prevention and vascular health – What’s on the horizon?

30 April 2017 (13:05 - 13:20)

Organised by:

About the speaker

Professor Keith Fox

University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Introduction & remarks.

Professor N. Danchin (Paris, FR)

Presentation thumbnail

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Professor M. Cowie (London, GB)

Presentation thumbnail

Broadening the evidence base for rivaroxaban in heart failure.

Professor B. Greenberg (La Jolla, US)

Presentation thumbnail

Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

Doctor R. Mentz (Durham, US)

Presentation thumbnail

Q&A and closing remarks.

Professor M. Cowie (London, GB)

Access the full session

Session thumbnail

Management of co-morbidities in heart failure - Exploring new frontiers

The Event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

30 April 2017 13:05 CET

You may be interested in

Congress Presentation

Contemporary thrombosis management -- state of the state

30 August 2024

ESC TV Today

Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals

5 June 2025

Congress Presentation

S1P receptor-1 signaling reduces arterial thrombosis by upregulation of endothelial thrombomodulin expression

26 August 2023

Congress Session

Maintaining vascular health to reduce CV risk

13 April 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources